Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients?

Despite a plethora of studies demonstrating significant morbidity and mortality due to community-acquired respiratory viral (CRV) infections in intensively treated hematology patients, and despite the availability of evidence-based guidelines for the diagnosis and management of respiratory viral inf...

Full description

Saved in:
Bibliographic Details
Published in:Microorganisms (Basel) 2019-11, Vol.7 (11), p.521
Main Authors: Popescu, Cristian-Marian, Ursache, Aurora Livia, Feketea, Gavriela, Bocsan, Corina, Jimbu, Laura, Mesaros, Oana, Edwards, Michael, Wang, Hongwei, Berceanu, Iulia, Neaga, Alexandra, Zdrenghea, Mihnea
Format: Article
Language:English
Subjects:
community respiratory viruses
Diagnosis
Epidemiology
Guidelines
hematological malignancy
Hematology
Influenza
intensive chemotherapy
Morbidity
Mortality
Pandemics
Patients
Respiratory syncytial virus
respiratory viral infections
Review
stem cell transplantation
Viral infections
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Despite a plethora of studies demonstrating significant morbidity and mortality due to community-acquired respiratory viral (CRV) infections in intensively treated hematology patients, and despite the availability of evidence-based guidelines for the diagnosis and management of respiratory viral infections in this setting, there is no uniform inclusion of respiratory viral infection management in the clinical hematology routine. Nevertheless, timely diagnosis and systematic management of CRV infections in intensively treated hematology patients has a demonstrated potential to significantly improve outcome. We have briefly summarized the recently published data on CRV infection epidemiology, as well as guidelines on the diagnosis and management of CRV infections in patients intensively treated for hematological malignancies. We have also assessed available treatment options, as well as mentioned novel agents currently in development.
ISSN:2076-2607
2076-2607
DOI:10.3390/microorganisms7110521